Clinical classification of pulmonary hypertension

Journal of the American College of Cardiology

Volumn 43, Issue 12 SUPPL., 2004, Pages S5-S12

  Simonneau, Gerald ^a,m   Galiè, Nazzareno ^b   Rubin, Lewis J ^c   Langleben, David ^d   Seeger, Werner ^e   Domenighetti, Guido ^f   Gibbs, Simon ^g   Lebrec, Didier ^h   Speich, Rudolf ⁱ   Beghetti, Maurice ^j   Rich, Stuart ^k   Fishman, Alfred ^l  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f Regional Hospital of Locarno   (Switzerland)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^h BEAUJON HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m HÔPITAL ANTOINE BÉCLÈRE   (France)

more..

Author keywords

activin receptor like kinase 1; ALK1; APAH; BMPR2; bone morphogenetic protein receptor type II; familial pulmonary arterial hypertension; FPAH; IPAH; pulmonary arterial hypertension related to risk factors or associated conditions

Indexed keywords

CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL PRACTICE; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG SCREENING; EMBOLISM; EUROPE; FOOD AND DRUG ADMINISTRATION; FRANCE; GENETIC ASSOCIATION; GENETIC DISORDER; HEMANGIOMATOSIS; HEMATOLOGIC DISEASE; HUMAN; HYPOXEMIA; LUNG ARTERIOVENOUS SHUNT; LUNG CAPILLARY; METABOLIC DISORDER; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TREATMENT INDICATION; UNITED STATES; VEIN OCCLUSION;

EID: 2942522878     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.02.037     Document Type: Conference Paper

References (71)

1. Hatano S., Strasser T. Primary Pulmonary Hypertension. Report on a WHO Meeting. 1975;World Health Organization, Geneva.:7-45
2. Rich S., Dantzer D.R., Ayres S.M., et al. Primary pulmonary hypertension a national prospective study. Ann Intern Med. 107:1987;216-228
3. Rich S, Rubin LJ, Abenhail L, et al. Executive summary from the World Symposium on Primary Pulmonary Hypertension (Evian, France, September 6-10, 1998). The World Health Organization publication via the Internet. Available at: http://www.who.int/ncd/cvd/pph.html
4. Fishman A.P. Clinical classification of pulmonary hypertension. Clin Chest Med. 22:2001;385-391
5. Humbert M., Nunes H., Sitbon O., et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med. 22:2001;459-475
6. Barst R.J., Rubin L.J., Long W.A. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 334:1996;296-302
7. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 132:2000;425-434
8. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 134:1997;44-54
9. Berry D.F., Buccigrossi D., Peabody J., et al. Pulmonary vascular occlusion and fibrosing mediastinitis. Chest. 89:1986;296-301
10. Mandel J., Mark E.J., Hales C.A. Pulmonary veno-occlusive disease. Am J Respir Care Med. 162:2000;1964-1973
11. Weitzenblum E., Sautegeau A., Ehrhart M., et al. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis. 130:1984;993-998
12. British Medical Research Council Party. Long-term domiciliary oxygen therapy in hypoxic cor pulmonale complicating bronchitis and emphysema. Lancet. 1:1981;681-685
13. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med. 93:1980;391-398
14. Jamieson S.W., Kapelanski D.P., Sakahibara N., et al. Pulmonary endarterectomy experience and lessons learned in 1, 500 cases. Ann Thorac Surg. 76:2003;1457-1464
15. Moser K.M., Auger W.R., Fedullo P.F. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation. 81:1990;1735-1743
16. Simonneau G., Azarian R., Brenot F., et al. Surgical management of unresolved pulmonary embolism. A personal series of 72 patients. Chest. 107:1995;52s-55s
17. Wagenvoort C.A., Beetsra A., Spijker J. Capillary hemangiomatosis of the lung. Histopathology. 2:1978;401-406
18. Schraufnagel D.E., Sekosan M., McGee T., et al. Human alvéolar capillaries undergo angiogenesis in pulmonary veno-occlusive disease. Eur Respir J. 9:1996;346-350
19. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension a randomised placebo-controlled study. Lancet. 358:2001;1119-1123
20. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 346:2002;896-903
21. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension a double-blind randomized controlled trial. Am J Respir Crit Care Med. 165:2002;800-804
22. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med. 347:2002;322-327
23. Lane KB, Machado RD, Pauciulo, et al., for the International PPH Consortium. Heterozygous germ-line mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-4
24. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet. 37:2000;741-745
25. Newman J.H., Wheeler L., Lane K.B., et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 345:2001;319-324
26. Humbert M., Deng Z., Simonneau G., et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J. 20:2002;518-523
27. Runo J.R., Vnencak-Jones C.L., Prince M., et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med. 167:2003;889-894
28. Morse J.H., Barst R.J., Horn E., et al. Pulmonary hypertension in scleroderma spectrum of disease lack of bone morphogenetic protein receptor-2 mutations. J Rheumatol. 29:2002;2379-2381
29. Eddahibi S., Humbert M., Fadel E., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 108:2001;1141-1150
30. Romberg E. Ueber sklerose der lungen arterie. Dtsch Archiv Klin Med. 48:1891;197-206
31. Dresdale D.T., Schultz M., Michtom R.J. Primary pulmonary hypertension. Clinical and hemodynamic study. Am J Med. 11:1951;686-705
32. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43 Suppl S:25S-32S
33. Daroca P.J., Mansfield R.E., Ichinose H. Pulmonary veno-occlusive disease report of a case with pseudoangiomatous features. Am J Surg Pathol. 12:1977;349-355
34. Pietra G.G. The pathology of primary pulmonary hypertension. Rubin L.J., Rich S. Primary Pulmonary Hypertension: Lung Biology in Health and Disease. 1997;19-61 Marcel Dekker, New York, NY
35. Humbert M., Maitre S., Capron F., et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Crit Care Med. 157:1998;1681-1685
36. Resten A., Maitre S., Musset D., et al. Pulmonary arterial hypertension; thin-section CT predictors of epoprostenol failure. Radiology. 222:2002;782-788
37. Dorfmüller P., Humbert M., Sanchez O., et al. Significant occlusive lesions of pulmonary veins are in common with pulmonary hypertension (PH) associated to connective tissue (CTD). (abstr) Am J Crit Care Med. 167:2003;A694
38. Ruchelli E.D., Nojadera G., Rutstein R.M., et al. Pulmonary veno-occlusive disease another vascular disorder associated with human immunodeficiency virus infection? Arch Pathol Lab Med. 118:1994;664-666
39. Escamilla R., Hermant C., Berjaud K.L., et al. Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser. Eur Respir J. 8:1995;1982-1984
40. Woordes C.G., Kuipers J.R.G., Elema J.D., et al. Familial pulmonary veno-occlusive disease a case report. Thorax. 32:1977;763-766
41. Langleben D., Heneghan J.M., Batten A.P., et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med. 109:1988;106-109
42. Rich S., Rubin L., Walker A.L., et al. Anorexigens and pulmonary hypertension in the United States results from the Surveillance of North American Pulmonary Hypertension. Chest. 117:2000;870-874
43. Langleben D, Walker AB, Korelitz JJ, et al. Temporal trends in the number of reported cases of pulmonary hypertension and use of anorexigens, antidepressants and amphetamines, between 1998 and 2001 (abstr). Am J Crit Care Med 2004. In press
44. Hoeper M.M., Niedermeyer J., Hoffmeyer F., et al. Pulmonary hypertension after splenectomy? Ann Intern Med. 130:1999;506-509
45. Castro O., Hoque M., Brown B.D. Pulmonary hypertension in sickle cell disease cardiac catheterization results and survival. Blood. 101:2003;1257-1261
46. Jison M.L., Gladwin M.T. Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Am J Respir Crit Care Med. 168:2003;3-4
47. Minter K.R., Gladwin M.T. Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment and research. Am J Respir Crit Care Med. 164:2001;2016-2019
48. Atichartakarn V., Likittanasombat K., Chuncharunee S., et al. Pulmonary arterial hypertension in previously splenectomized patients with β-thalassemic disorders. Int J Hematol. 78:2003;139-145
49. Marvin K.S., Spellberg R.D. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest. 103:1993;642-644
50. Rostagno C., Prisco D., Abbate R., et al. Pulmonary hypertension associated with long-standing thrombocytosis. Chest. 99:1991;1303-1305
51. Garcia-Manero G., Schuster S.J., Patrick H., et al. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol. 60:1999;130-135
52. Dingli D., Utz J.P., Krowka M.J., et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest. 120:2001;801-808
53. Pizzo C.J. Type 1 glycogen storage disease with focal nodular hyperplasia of the liver and vasoconstrictive pulmonary hypertension. Pediatrics. 65:1980;341-343
54. Lei K.J., Chen Y.T., Chen H. Genetic basis of glycogen storage disease type I prevalent mutations at the glucose-6-phosphatase locus. Am J Hum Genet. 57:1995;766-771
55. Humbert M., Labrune P., Sitbon O., et al. Pulmonary arterial hypertension and type-I-glycogen-storage disease the serotonin hypothesis. Eur Respir J. 20:2002;59-65
56. Dawson A., Elias D.J., Rubenson D., et al. Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med. 125:1996;901-912
57. Morse J.H. Bone morphogenetic protein receptor-2 mutations in pulmonary hypertension. Chest. 121:2002;50S-53S
58. Sapru R.P., Hutchison D.C., Hall J.I. Pulmonary hypertension in patients with pulmonary arteriovenous fistulae. Br Heart J. 31:1969;559-569
59. Trell E., Johansson B.W., Linell F., et al. Familial pulmonary hypertension and multiple abnormalities of large systemic arteries in Osler's disease. Am J Med. 53:1972;50-63
60. Trembath R.C., Thomson J.R., Machado R.D., et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 345:2001;325-334
61. Chaouat A, Coulet F, Favre C, et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004. In press
62. Eisenmenger V. Die angeboren defects des kammerscheidewand des herzen]. Z Klin Med. 32:1897;1-28
63. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J. 2:1958;701-709
64. Kidd L., Driscoll D., Gersony W., et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation. 87:1993;138-151
65. Morse J.H., Barst R.J., Fotino M. Familial pulmonary hypertension immunogenetic findings in four Caucasian kindreds. Am Rev Respir Dis. 145:1992;787-792
66. Daliento L., Somerville J., Presbitero P., et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 19:1998;1845-1855
67. Battesti J.P., Georges R., Basset F., et al. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax. 33:1978;76-84
68. Takemura T., Matsui Y., Saiki S., et al. Pulmonary vascular involvement in sarcoidosis a report of 40 autopsy cases. Hum Pathol. 23:1992;1216-1223
69. Fartoukh M., Humbert M., Capron F., et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med. 161:2000;216-223
70. Harari S., Simonneau G., De Juli E., et al. Prognosis value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant. 16:1997;460-463
71. Craussman R.S., Jennings C.A., Tuder R.M., et al. Pulmonary histiocytosis X pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med. 153:1996;426-435